Exelixis
Update in progressEXEL (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Exelixis, Inc. is an oncology company focused on discovering, developing and commercializing medicines for difficult-to-treat cancers in the United States. Its approved therapies include CABOMETYX for advanced renal cell carcinoma after anti-angiogenic therapy and COMETRIQ for progressive/metastatic medullary thyroid cancer. It also markets COTELLIC and MINNEBRO and maintains a broad pipeline and collaborations. Headquartered in Alameda, California; incorporated 1994; renamed in 2000.
Company score
- Sentiment
- 0.14
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.08
- Governance
- -0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.05
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Michael M. Morrissey Ph.D.
- Founded1994
- Employees1,077
- Websitewww.exelixis.com
Identifiers
- ISINUS30161Q1040
- FIGIBBG000BQ4WF8
- CUSIP30161Q104
- CIK0000939767